Charles River Laboratories Projects Strong 2026 Profits as Biotech Demand Stabilizes
Charles River Laboratories forecasts 2026 adjusted earnings of $10.70-$11.20 per share, exceeding Wall Street expectations, as biotech demand for drug research services recovers and contract cancellations decline.
Charles River Laboratories announced Wednesday it expects 2026 profits to exceed Wall Street predictions, citing recovering demand from biotechnology companies for drug research services. The Massachusetts-based contract research firm projects its adjusted earnings for 2026 will fall between $10.70 and $11.20 per share. The midpoint of this forecast surpasses the average Wall Street prediction of $10.88 per share, based on LSEG data.
The research firm has observed a rise in project proposals from pharmaceutical and biotech companies, while contract cancellations have decreased. Those earlier cancellations stemmed from clients responding to the federal government's drug pricing negotiation initiative.
The CEO highlighted the positive trend, stating that fourth-quarter "net bookings… demonstrates the stabilization of the biopharmaceutical demand environment." The CEO added that the company remains "cautiously optimistic that positive demand trends will continue in 2026."
For the fourth quarter, Charles River reported revenue of $994.2 million, marking no change from the previous year but 1.4% above analyst expectations of $987 million. The company's fourth-quarter adjusted earnings per share reached $2.39, surpassing the analyst consensus estimate of $2.34.
Despite the revenue beat, the company noted that quarterly sales were dampened by reduced volume in both drug discovery services and regulated safety assessment services compared to the previous year.
Looking ahead to 2026, Charles River anticipates revenue growth ranging from flat to a 1.5% increase.
The company also revealed executive changes Wednesday, naming Glenn Coleman as its new finance chief to replace interim CFO Michael Knell. Kerry Dailey will assume the newly established role of chief legal officer. The CEO's retirement was announced last month, with Chief Operating Officer Birgit Girshick set to take over leadership in May.
Founded in 1947 and named after the Massachusetts river, Charles River Laboratories provides non-clinical drug development services, research models, and manufacturing support to pharmaceutical and biotech companies. Since the earnings report, the stock has climbed 12.6% and is now trading at $178.54.